186 related articles for article (PubMed ID: 1665568)
1. Effects of antiplatelet agents on platelet aggregation induced by platelet--activating factor (PAF) in human whole blood.
Chan WP; Levy JV
Prostaglandins; 1991 Oct; 42(4):337-42. PubMed ID: 1665568
[TBL] [Abstract][Full Text] [Related]
2. Platelet-activating factor (PAF) receptor antagonists inhibit arachidonic acid induced platelet aggregation in rabbit whole blood.
Ammit AJ; O'Neill C
Lipids; 1991 Dec; 26(12):1189-92. PubMed ID: 1668116
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PAF-induced platelet aggregation by WEB 2086 'in-vitro', an antagonist to the receptor for platelet-activating factor, in bovine.
da Silva MB; Herion F; Raskinet R; David JL; Gustin P; Dessy C; Lekeux P
Zentralbl Veterinarmed A; 1996 Sep; 43(7):399-413. PubMed ID: 8921726
[TBL] [Abstract][Full Text] [Related]
4. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse.
Foster AP; Lees P; Andrews MJ; Cunningham FM
Equine Vet J; 1992 May; 24(3):203-7. PubMed ID: 1318830
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
8. Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
Montrucchio G; Alloatti G; Mariano F; Lupia E; Lucchina PG; Musso E; Emanuelli G; Camussi G
Circ Res; 1993 Mar; 72(3):658-70. PubMed ID: 8381725
[TBL] [Abstract][Full Text] [Related]
9. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086.
Griffin K; Hong T; Levy JV
Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
11. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.
Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J
Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017
[TBL] [Abstract][Full Text] [Related]
12. Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation.
Lee LW; Peng HC; Ko WC; Hung WC; Su CH; Lin CH; Huang TF; Yen MH; Sheu JR
Eur J Pharmacol; 1999 Jan; 364(2-3):239-46. PubMed ID: 9932729
[TBL] [Abstract][Full Text] [Related]
13. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
Koike H; Imanishi N; Natsume Y; Morooka S
Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
[TBL] [Abstract][Full Text] [Related]
14. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
15. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
[TBL] [Abstract][Full Text] [Related]
16. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
Salari H; Dryden P; Howard S; Bittman R
Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
[TBL] [Abstract][Full Text] [Related]
17. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
18. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking.
Lehr HA; Weyrich AS; Saetzler RK; Jurek A; Arfors KE; Zimmerman GA; Prescott SM; McIntyre TM
J Clin Invest; 1997 May; 99(10):2358-64. PubMed ID: 9153277
[TBL] [Abstract][Full Text] [Related]
19. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
Grigoriadis G; Stewart AG
Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
[TBL] [Abstract][Full Text] [Related]
20. Combined effect of Web 2086 (Paf antagonist) and ketoprofen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine.
Bastos da Silva M; Herion F; Raskinet R; David JL; Gustin P; Lekeux P
Zentralbl Veterinarmed A; 1997 Apr; 44(2):65-71. PubMed ID: 9284631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
